BioBlast merging with Enlivex

BioBlast Pharma Ltd. (NASDAQ:ORPN) will merge with Enlivex Therapeutics Ltd. (Jerusalem, Israel), which is developing its Allocetra cell therapy program. In 4Q19, Enlivex expects to begin a Phase II trial of the therapy to treat steroid-refractory graft-versus-host disease (GvHD) and a Phase II/III trial to prevent GvHD in bone marrow transplant patients. The company anticipates beginning a Phase II trial in 2Q19 to treat sepsis.

The resulting company will retain Enlivex's name. ...